Patient Name :Mr.

VINIT DESWAL
Age/Sex : 33 YRS/M Lab Id. : 011912120031
Refered By : Self Sample Collection On : 12/Dec/2019 06:55AM
Collected By :SHUBHAM RAJPUT Sample Lab Rec.On :12/Dec/2019 12:35 PM
Collection Mode :HOME COLLECTION Reporting On :12/Dec/2019 12:51 PM
BarCode :10131251

AAROGYA EXECUTIVE PACKAGE 109 TEST

Lipid Profile (Heart Risk Profile),Serum
TOTAL CHOLESTEROL SERUM 211H 130-200 mg/dl
(Method : CHOD-PAP)
The purpose of this test is to check/monitor blood cholesterol level. Serum cholesterol is used as an indicator of
atherosclerosis, coronary artery disease and is an important screening test for heart disease.
Condition associated with increased cholesterol levels : Familial (hereditary) tendency, abnormal dietary intake,
alcoholism, hypothyroidism, Acute MI, nephrotic syndrome, pancreaectomy, billiary obstruction, pregnancy (third
trimester), dru influence such as aspirin, corticosteroids, steroids, oral contraceptives, vitamin A & D, etc
Condition associated with decreased cholesterol levels: Hypo-alpha lipoproteinemia, Hyperthyroidism, Malabsorption
syndrome, starvation, chronic anemia etc
People with increased cholesterol levels are advised to undergo: Lipid Profile and Apolipoprotein A & B at regular
intervals.
TRIGLYCERIDES SERUM 100.7 30-150 mg/dl
(Method : GPO )
Triglycerides are blood lipids formed by esterification of glycerol and three fatty acids and are carried by the serum
lipoproteins. The intestine processes the triglycerides from dietary fatty acid and they are transported in the blood
stream as chylomicrones. A function of triglycerides is to provide energy to heart and skeletal muscles. Triglycerides
are major contributor to arterial diseases. As the concentration of triglycerides increases, so will the VLDL
increases. A peak concentration of chylomicron associated triglycerides occurs within 3-6 hrs after ingestion of fat
rich meal. Alcohol intake also causes transient increase of serum TG level. If TG is more than 400 mg/dL, VLDL cannot
be calculated.
Conditions associated with increased TG levels: Hyperlipoproteinemia, stress, high carbohydrate or fatty diet, acute
MI, hypertension, cerebral thrombosis, hypothyroidism, uncontrolled diabetes, pancreatitis, pregnancy etc.
Conditions associated with decreased TG levels: Hyperthyroidism, Hyperparathyroidism, Lipoproteinemia, protein
malnutrition, exercise etc.
People with increased levels are advised to undergo Lipid Profile at regular intervals, Apolipoprotein A & B

HIGH DENSITY LIPOPROTEIN CHOLESTEROL 43 35 - 80 mg/dl

(Method : HDL DIRECT)

Page 1 of 16
 Patient Name :Mr.VINIT DESWAL
Age/Sex : 33 YRS/M Lab Id. : 011912120031
Refered By : Self Sample Collection On : 12/Dec/2019 06:55AM
Collected By :SHUBHAM RAJPUT Sample Lab Rec.On :12/Dec/2019 12:35 PM
Collection Mode :HOME COLLECTION Reporting On :12/Dec/2019 12:51 PM
BarCode :10131251

AAROGYA EXECUTIVE PACKAGE 109 TEST

VERY LOW DENSITY LIPOPROTEIN VLDL 20.14 7 - 34 mg/dl
(Method : Calculated)

LOW DENSITY LIPOPROTEIN BAD CHOLESTEROL 147.56H 63 - 129 mg/dl

(Method : Calculated)

TOTAL CHOLESTEROL / HDL CHOLESTEROL 4.87H 0.1 - 4.0 Ratio

(Method : Calculated)

LDL / HDL CHOLESTEROL RATIO * 3.41 1.5 - 3.5 Ratio

(Method : Calculated)

NON- HDL CHOLESTEROL * 167.7H < 160 mg/dl

(Method : Calculated)

TOTAL LIPID * 502.56 400 - 1000 mg/dl

(Method : Calculated)

Extended Liver Profile (Liver Function Test),Serum

BILIRUBIN TOTAL 0.78 0.1-1.20 mg/dL
(Method : DIAZO)

BILIRUBIN DIRECT 0.20 0.0 - 0.20 mg/dl

(Method : DIAZO)

BILIRUBIN INDIRECT 0.58 0.00 - 1.00 mg/dl

(Method : Calculated)

PROTEIN TOTAL SERUM 6.6 6.4-8.3 gm/dL

(Method : Biuret End Point)

ALBUMIN SERUM 4.26 3.5-5.2 g/dL

(Method : BCG )

GLOBULIN SERUM 2.34 2.0-3.5 mg/dL

(Method : Calculated)

ALBUMIN / GLOBULIN RATIO 1.82 1.2 - 2.5 Ratio

(Method : Calculated)

Page 2 of 16
 Patient Name :Mr.VINIT DESWAL
Age/Sex : 33 YRS/M Lab Id. : 011912120031
Refered By : Self Sample Collection On : 12/Dec/2019 06:55AM
Collected By :SHUBHAM RAJPUT Sample Lab Rec.On :12/Dec/2019 12:35 PM
Collection Mode :HOME COLLECTION Reporting On :12/Dec/2019 12:51 PM
BarCode :10131251

AAROGYA EXECUTIVE PACKAGE 109 TEST

SGOT / AST 18.1 0 - 35 U/L
(Method : IFCC Method Kinetic )

SGPT / ALT 23.7 0-45 U/L

(Method : IFCC Method Kinetic )

SGOT/SGPT Ratio 0.76

GAMMA GT * 21 0 - 50 U/l
Gamma Glutamyl Transferase is an enzyme premarily found in the liver and kidney, with smalleramount in spleen,
prostate gland, and heart muscle.

GGT is sensitive in detecting liver diseases, especially in biliary obstruction. The serum level will rise early and
remain elevated as long as cellular damage persists.

Condition associated with increased GGT levels : Alcoholism, cholestasis cirrhosis, acute and subacute necrosis if
liver, acute and chronic hepatitis, cancer (Liver pancreas, prostate, breast, kidney, lung, brain) hemochromatosis,
diabetes mellitus, drugs such as phenytoin, phenobarbital, aminoglycosides, warfarin, etc High levels of GGT can occur
after 12 to 24 hours of heavy alcoholic drinking and may remain increased for 2 to 3 weeks after stopping alcohol
intake.

People with increased GGT levels are recommended to undergo : Prothrobin Time, repeat LFT at 1-2 weeks, HBsAg, Anti
HCV, Antibodies to Hepatitis A & E
ALKALINE PHOSPHATASE (ALP) 102 53-128 U/L
(Method : AMP)

LDH * 254 200 - 450 U/l

(Method : DGKC,Kinetic)

Kidney Function Test (KFT),Serum

BLOOD UREA 21.8 12-43 mg/dL
(Method : Urease-GLDH)

BLOOD UREA NITROGEN (BUN) * 10 6 - 21 mg/dl

(Method : Calculated)

Page 3 of 16
 Patient Name :Mr.VINIT DESWAL
Age/Sex : 33 YRS/M Lab Id. : 011912120031
Refered By : Self Sample Collection On : 12/Dec/2019 06:55AM
Collected By :SHUBHAM RAJPUT Sample Lab Rec.On :12/Dec/2019 12:35 PM
Collection Mode :HOME COLLECTION Reporting On :12/Dec/2019 12:51 PM
BarCode :10131251

AAROGYA EXECUTIVE PACKAGE 109 TEST

SERUM CREATININE 1.33 0.6-1.40 mg/dL
(Method : Modified Jaffe,s)

Creatinine is a by product of muscle catabolism. It is filtered by kidney and excreted in the urine. if the filtering of the kidney is deficient, creatinine levels in blood are
increased.

Creatine level is used for the assessment of kidney function and to diagnose renal dysfunction. However, more important than absolute creatinine level is the trend of serum
creatinine levels over time. Serum creatine is especially useful in evaluation of glomerular function. BUN (Blood Urea Nitrogen) & Creatine are frequently compared. If BUN
increased and creatinine is normal, dehydration is present; and if both increased, then renal disorder is present.

Conditions associated with increased creatine level : Acute and chronic renal failure, shock (prolonged), systemic lupus erythematosis, cancer, leukemia , hypertension,
acute myocardial infaction, diabetic nephropathy , diet rich in creatinine (e.g. beef), congenital renal disease etc.

Condition associated with decreased creatine level : Pregnancy, Eclampsia etc.

Opinion & Advice:

People with increased creatine levels are advised to undergo : Kidney Function Test, Urine Examination & USG (Whole abdomen) at regular intervals.
Decreased creatine levels are usually insignificant.
SERUM URIC ACID 4.8 3.5-7.2 mg/dL
(Method : Uricase-POD)

UREA / CREATININE RATIO * 16.39L 23 - 33 Ratio

(Method : Calculated)

BUN / CREATININE RATIO * 7.66 5.5 - 19.2 Ratio

(Method : Calculated)

GFR * 69.74 mL/min/1.73

m2
(Method : Calculated)

Reference Range :-

> = 90 : Normal
60 - 89 : Mild Decrease

Page 4 of 16
 Patient Name :Mr.VINIT DESWAL
Age/Sex : 33 YRS/M Lab Id. : 011912120031
Refered By : Self Sample Collection On : 12/Dec/2019 06:55AM
Collected By :SHUBHAM RAJPUT Sample Lab Rec.On :12/Dec/2019 12:35 PM
Collection Mode :HOME COLLECTION Reporting On :12/Dec/2019 12:51 PM
BarCode :10131251

60 - 89 : Mild Decrease AAROGYA EXECUTIVE PACKAGE 109 TEST

45 - 59 : Mild to Moderate Decrease
30 - 44 : Moderate to Severe Decrease
15 - 29 : Severe Decrease

Clinical Significance

The normal serum creatinine reference interval does not necessarily reflect a normal GFR for a patient. Because mild and moderate kidney
injury is poorly inferred from serum creatinine alone. Thus, it is recommended for clinical laboratories to routinely estimate glomerular
filtration rate (eGFR), a “gold standard” measurement for assessment of renal function, and report the value when serum creatinine is
measured for patients 18 and older, when appropriate and feasible. It cannot be measured easily in clinical practice, instead, GFR is
estimated from equations using serum creatinine, age, race and sex. This provides easy to interpret information for the doctor and patient
on the degree of renal impairment since it approximately equates to the percentage of kidney function remaining. Application of CKD-EPI
equation together with the other diagnostic tools in renal medicine will further improve the detection and management of patients with
CKD.

Reference

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate.
Ann Intern Med. 2009;150(9):604-12.
INORGANIC PHOSPHORUS 3.36 2.5-4.5 mg/dL
(Method : UV Molybdate)

Electrolyte Profile
SODIUM (Na+) 138.6 135 - 145 mmol/L
(Method : ISE)

POTASSIUM (K+) 4.52 3.5 - 5.5 mmol/L

Page 5 of 16
 Patient Name :Mr.VINIT DESWAL
Age/Sex : 33 YRS/M Lab Id. : 011912120031
Refered By : Self Sample Collection On : 12/Dec/2019 06:55AM
Collected By :SHUBHAM RAJPUT Sample Lab Rec.On :12/Dec/2019 12:35 PM
Collection Mode :HOME COLLECTION Reporting On :12/Dec/2019 12:51 PM
BarCode :10131251

AAROGYA EXECUTIVE PACKAGE 109 TEST

(Method : ISE)

CHLORIDE(Cl-) 104.99 96.0 - 106 mmol/L

(Method : ISE)

TOTAL CALCIUM (Ca) 9.6 8.8-10.8 mg/dL

(Method : Arsenazo )

IONIZED CALCIUM * 4.69 4.4 - 5.4 mg/dl

(Method : ISE)
Comments
Clinical Significance
Hypercalcemia ( Increased ionized calcium )
- Increased intestinal absorption.
- Increased mobilization from bone.
- Decreased renal elimination.
- Addison's disease.
Hypocalcemia ( decreased ionized calcium )
- Decreased intestinal absorption.
- Increased renal elimination.
- Increased deposition of calcium in bones.
- Increased binding to proteins when Ph increases or binding to citrate.
- Hypoparathyrodism.
NON-IONIZED CALCIUM * 4.81 4.4 - 5.4 mg/dl
(Method : ISE)

pH. 7.38 7.35 - 7.45

ARTHRITIS SCREENING
ALKALINE PHOSPHATASE (ALP) 102 53-128 U/L
(Method : AMP)

MAGNESIUM * 1.62 1.5 - 2.3 mg/dl

RA - FACTOR (QUANTITATIVE) * 5.2 0 - 20 IU/ml
INTERPRETATION
< 20 Iu/ml = Negative

Page 6 of 16
 Patient Name :Mr.VINIT DESWAL
Age/Sex : 33 YRS/M Lab Id. : 011912120031
Refered By : Self Sample Collection On : 12/Dec/2019 06:55AM
Collected By :SHUBHAM RAJPUT Sample Lab Rec.On :12/Dec/2019 12:35 PM
Collection Mode :HOME COLLECTION Reporting On :12/Dec/2019 12:51 PM
BarCode :10131251

AAROGYA EXECUTIVE PACKAGE 109 TEST

ADVANTAGES OF QUANTITATION :-
Exact concentrations of RA Factor facilitate the following:
* Accurate staging of disease.
* Precise prognosis and indication of complications.
* Adjustment of dose for treatment and follow up of treatment.
REMARKS :-
* RA factor has been demonstrated in approximately 80 % of patients with rheumatoid arthritis.
* False positive results may occur in hepatitis, sarcoidosis, cirrhosis of liver.
Sjogren's syndrome, acute bacterial and viral infection.
* Diagnosis of rheumatoid arthritis should be made in conjuction with complete clinical evaluation.
need for individual testing. ENA SCREEN is there fore a cost effective and quick test for screening rheumatic process.

CRP (QUANTITATIVE) * 2.6 0-6 mg/L

(Method : Latex )
INTERPRETATION :-

In normal healthy individuals, CRP levels generally do not Exceed 10 mgm/L. CRP plays a role in host defence and tissue repair. There is a lag time of 6 -10 hrs between
stimulus and rise in serum levels, as compared to a lag time of 24-72 hrs, for other acute phase reactant

ASO QUANTITATIVE (ANTI STROPTOLYSION O) * 123.5 0 - 200 IU/ml

ERYTHROCYTE SEDIMENTATION RATE (ESR) 15 0.0 - 15.0 mm/Ist hr.
(Method : Modified Westergreen)

DIABETES PROFILE
BLOOD SUGAR FASTING,Plasma Floride 75.4 70 - 110 mg/dl
(Method : GOD-POD)

GLUCOSE IN URINE Negative Negative

(Method : GOD/POD)

HbA1C (GLYCOSYLATED HAEMOGLOBIN),EDTA * 4.1 4.0 - 6.0 %

(Method : HPLC)

Page 7 of 16
 Patient Name :Mr.VINIT DESWAL
Age/Sex : 33 YRS/M Lab Id. : 011912120031
Refered By : Self Sample Collection On : 12/Dec/2019 06:55AM
Collected By :SHUBHAM RAJPUT Sample Lab Rec.On :12/Dec/2019 12:35 PM
Collection Mode :HOME COLLECTION Reporting On :12/Dec/2019 12:51 PM
BarCode :10131251

AAROGYA EXECUTIVE PACKAGE 109 TEST

EXPECTED VALUES :-
Metabolicaly healthy patients : 4.48 -5.5 % HbAIC
Good Control : 5.5 – 6.0 % HbAIC
Fair Control : 6.0 – 7.0 % HbAIC
Poor Control : > 7.0 % HbAIC
In vitro quantitative determination of HbAIC in whole blood is utilized in long term monitoring of glycemia. The HbAIC
level correlates with the mean glucose concentration prevailing in the course of the patient's recent history (approx
- 6-8 weeks) and therefore provides much more reliable information for glycemia monitoring than do determinations of
blood glucose or urinary glucose.
It is recommended that the determination of HbAIC be performed at intervals of 6-8 weeks during Diabetes Mellitus
therapy.
Results of HbAIC should be assessed in conjunction with the patient's medical history, clinical examinations and other
findings.
ESTIMATED AVERAGE PLASMA GLUCOSE * 70.97 70-180 mg/dL
(Method : Calculated)

Page 8 of 16
 Patient Name :Mr.VINIT DESWAL
Age/Sex : 33 YRS/M Lab Id. : 011912120031
Refered By : Self Sample Collection On : 12/Dec/2019 06:55AM
Collected By :SHUBHAM RAJPUT Sample Lab Rec.On :12/Dec/2019 12:35 PM
Collection Mode :HOME COLLECTION Reporting On :12/Dec/2019 02:17 PM
BarCode :10131251

AAROGYA EXECUTIVE PACKAGE 109 TEST

THYROID PROFILE,Serum
TRIIODOTHYRONINE - T3 0.96 0.80-2.0 ng/ml
(Method : CLIA)

THYROXINE - T4 8.47 6.09 - 12.23 ug/dL

(Method : CLIA)

THYROID STIMULATINGHORMONE - TSH 1.838 0.35 - 5.50 uIU/mL

(Method : CLIA)

Pregnancy reference ranges for TSH

1st Trimester : 0.10 - 2.50
2nd Trimester : 0.20 - 3.00
3rd Trimester : 0.30 - 3.00
Reference: Guidelines of American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and
Postpartum, Thyroid, 2011, 21; 1-46

COMMENTS:
The levels of Thyroid hormones (T3, T4 & FT3, FT4) are low in case of Primary, Secondary and Tertiary hypothyroidism and sometimes
in nonthyroidal illness also. Increase levels are found in Grave’s disease, Hyperthyroidism and Thyroid Hormone resistance. TSH levels are
raised in Primary Hypothyroidism and are low in Hyperthyroidism and secondary hypothyroidism.

NOTE:
TSH levels are subject to circadian variation, reaction peak levels between 2-4 am and at a minimum between 6-10 pm. The variation is of
the day has influence on the measured serum TSH concentrations.
TSH values <0.03 uIU/ml need to be clinically correlated due to presence of a rare TSH variant in some individuals.

Page 9 of 16
 Patient Name :Mr.VINIT DESWAL
Age/Sex : 33 YRS/M Lab Id. : 011912120031
Refered By : Self Sample Collection On : 12/Dec/2019 06:55AM
Collected By :SHUBHAM RAJPUT Sample Lab Rec.On :12/Dec/2019 12:35 PM
Collection Mode :HOME COLLECTION Reporting On :12/Dec/2019 02:17 PM
BarCode :10131251

AAROGYA EXECUTIVE PACKAGE 109 TEST

VITAMIN PROFILE,Serum
VITAMIN D 25 HYDROXY * 74.6 30 - 100 ng/ml
(Method : CLIA)

SERUM VITAMIN B12 * 357 75 - 807 pg/ml

(Method : CLIA)

Vitamin B12 (cobalamin) is an important water-soluble vitamin. In contrast to other water-soluble

vitamins it is not excreted quickly in the urine, but rather accumulates and is stored in the liver,
kidney and other body tissues. Humans obtain Vitamin B12 exclusively from animal dietary sources, such
as meat, eggs and milk. As a result, a vitamin B12 deficiency may not manifest itself until after 5 or 6
years of a diet supplying inadequate amounts. Vitamin B12 functions as a methyl donor and works with
folic acid in the synthesis of DNA and red blood cells and is vitally important in maintaining the
health of the insulation sheath (myelin sheath) that surrounds nerve cells.

Vitamin B12 is necessary for hematopoiesis and normal neuronal function. B12 deficiency may be due to
lack of intrinsic factor secretion by gastric mucosa (gastrectomy, gastric atrophy) or intestinal
malabsorption leading to Macrocytic anemia. This assay is useful for investigating Macrocytic anemia and
as a workup of deficiencies seen in Megaloblastic anemia.

Page 10 of 16
 Patient Name :Mr.VINIT DESWAL
Age/Sex : 33 YRS/M Lab Id. : 011912120031
Refered By : Self Sample Collection On : 12/Dec/2019 06:55AM
Collected By :SHUBHAM RAJPUT Sample Lab Rec.On :12/Dec/2019 12:35 PM
Collection Mode :HOME COLLECTION Reporting On :12/Dec/2019 02:18 PM
BarCode :10131251

AAROGYA EXECUTIVE PACKAGE 109 TEST

Complete Blood Count (CBC),Whole Blood EDTA
Hemoglobin (Hb) 14.6 13.0-18.0 gm/dL
(Method : Photometric)

Red Blood Cell Count (RBC) 5.2 4.5-6.5 10^6/uL

(Method : Impedance)

RBC Distribution Width (RDW-CV) 15.3 11.0-16.0 %

(Method : Calculated)

RBC Distribution Width (RDW-SD) 44 35.0-56.0 FL

(Method : Calculated)

Mean Corpuscular Volume (MCV) 81.8 77-96 fL

(Method : Calculated)

Mean Corpuscular Haemoglobin (MCH) 28.3 27-33 Picogram

(Method : Calculated)

Mean Corpuscular Hb Concentration(MCHC) 34.6 30-35 g/dL

(Method : Calculated)

Haematocrit / PCV / HCT 42.2 40-54 %

(Method : Calculated)

Total Leucocyte Count (TLC) 5500 4000-11000 /cumm

(Method : Flow cytometry)

DIFFERENTIAL LEUCOCYTE COUNT(DLC)

NEUTROPHIL 53.07 40-75 %
(Method : Flow cytometry)

LYMPHOCYTE 34.70 20-40 %

(Method : Flow cytometry)

EOSINOPHIL 3.46 1.0 - 6.0 %

(Method : Flow cytometry)

MONOCYTE 8.59 2.0 - 10.0 %

Page 11 of 16
 Patient Name :Mr.VINIT DESWAL
Age/Sex : 33 YRS/M Lab Id. : 011912120031
Refered By : Self Sample Collection On : 12/Dec/2019 06:55AM
Collected By :SHUBHAM RAJPUT Sample Lab Rec.On :12/Dec/2019 12:35 PM
Collection Mode :HOME COLLECTION Reporting On :12/Dec/2019 02:18 PM
BarCode :10131251

AAROGYA EXECUTIVE PACKAGE 109 TEST

MONOCYTE 8.59 2.0 - 10.0 %
(Method : Flow cytometry)

BASOPHIL 0.18 0.0 - 1.0 %

(Method : Flow cytometry)

ABSOLUTE NEUTROPHIL COUNT(ANC) 2.9 2.0 - 7.0 10^3 / uL

(Method : Flow cytometry)

ABSOLUTE LYMPHOCYTE COUNT (ALC) 1.9 1.0 - 3.0 10^3 / uL

(Method : Flow cytometry)

ABSOLUTE EOSINOPHIL COUNT (AEC) 0.2 0.04 - 0.44 10^3 / uL

(Method : Flow cytometry)

ABSOLUTE MONOCYTE COUNT(AMC) 0.5 0.2 - 1.0 10^3 / uL

(Method : Flow cytometry)

ABSOLUTE BASOPHIL COUNT 0 0.0 - 0.100 10^3 / uL

(Method : Flow cytometry)

Platelet Count 160 150-450 10^3/ul

(Method : Impedence)

MPV 8.4 6.5 - 12 fL

(Method : Calculated)

PDW 15.7 9.0-17.0

(Method : Calculated)

PCT 0.14 0.108-0.282 %

(Method : Calculated)

ANEMIA STUDIES
Iron (fe) * 77.6 65 - 170 ugm/dl
UIBC * 199.3 120 - 470 ug/dl
TIBC 276.90 228-428 ug/dl
(Method : Calculated)

Page 12 of 16
 Patient Name :Mr.VINIT DESWAL
Age/Sex : 33 YRS/M Lab Id. : 011912120031
Refered By : Self Sample Collection On : 12/Dec/2019 06:55AM
Collected By :SHUBHAM RAJPUT Sample Lab Rec.On :12/Dec/2019 12:35 PM
Collection Mode :HOME COLLECTION Reporting On :12/Dec/2019 02:18 PM
BarCode :10131251

AAROGYA EXECUTIVE PACKAGE 109 TEST

TRANSFERRIN SERUM * 242.89 215 - 365 mg/dl
(Method : Calculated)

% Saturation Transferrin * 28.02 16 - 50 %

(Method : Calculated)

Hemoglobin (Hb) 14.6 13.0-18.0 gm/dL

(Method : Photometric)

Red Blood Cell Count (RBC) 5.2 4.5-6.5 10^6/uL

(Method : Impedance)

Haematocrit / PCV / HCT 42.2 40-54 %

(Method : Calculated)

Page 13 of 16
 Patient Name :Mr.VINIT DESWAL
Age/Sex : 33 YRS/M Lab Id. : 011912120031
Refered By : Self Sample Collection On : 12/Dec/2019 06:55AM
Collected By :SHUBHAM RAJPUT Sample Lab Rec.On :12/Dec/2019 12:35 PM
Collection Mode :HOME COLLECTION Reporting On :12/Dec/2019 02:17 PM
BarCode :10131251

AAROGYA EXECUTIVE PACKAGE 109 TEST

Complete Urine Examination,Urine
PHYSICAL EXAMINATION
VOLUME 20
COLOUR Pale Yellow Pale Yellow
APPEARANCE Clear
pH 6.0 5.5 - 7.0
SPECIFIC GRAVITY 1.01 1.010-1.025
Chemical Examination
GLUCOSE IN URINE Negative Negative
(Method : GOD/POD)

PROTEIN Negative Negative

(Method : Protein error of a ph indicator)

UROBILIOGEN Normal Normal

(Method : Ehrlic)

BILE SALT * Negative Negative

(Method : Hey,s sulphar )

BILE PIGMENT * Negative Negative

(Method : Fouchet,s )

BILIRUBIN Negative Negative

(Method : Diazo)

KETONE Negative Negative

(Method : Legal,s)

BLOOD Negative Negative

(Method : Oxidation)

Page 14 of 16
 Patient Name :Mr.VINIT DESWAL
Age/Sex : 33 YRS/M Lab Id. : 011912120031
Refered By : Self Sample Collection On : 12/Dec/2019 06:55AM
Collected By :SHUBHAM RAJPUT Sample Lab Rec.On :12/Dec/2019 12:35 PM
Collection Mode :HOME COLLECTION Reporting On :12/Dec/2019 02:17 PM
BarCode :10131251

AAROGYA EXECUTIVE PACKAGE 109 TEST

NITRITE Negative Negative
(Method : Griess,s)

LEUKOCYTES Negative Negative

(Method : Granulocyte esterases&diazonium)

ASCORBIC ACID (Semi-Quantitative) Negative Negative

(Method : Tillman,s)

URINARY CALCIUM (Semi-Quantitative) Normal Normal

(Method : OCPC)

URINE CREATININE (Semi-Quantitative) Normal Normal

(Method : 3,5-Dinitrobenzoic)

MICROALBUMIN (Semi-Quantitative) Normal Normal

(Method : Reaction with fluorescein dye)

Kidney function may be accessed through measurement of albumin levels in the urine. Kidney mal function
results when the capillaries in the kidney become blocked, causing waste products to remain in the blood and important
proteins are lost from the blood into the urine. Kidney deterioration is progressive and begins with small amounts of
albumin leaking into the urine. This is known as microalbuminuria and indicates early signs of nephropathy. The term
'micro' refers to low concentrations of urinary albumin.Progression of kidney disease will lead to larger amounts of
albumin leaking into the urine which may develop further to end stage renal disease. Kidney disease is a major concern
in diabetes patients and early detection and treatment may slow the onset and progression of the condition.

Microscopic Examination
PUS CELLS 2-3 0-5 /HPF
RBC Negative Negative /HPF

Page 15 of 16
 Patient Name :Mr.VINIT DESWAL
Age/Sex : 33 YRS/M Lab Id. : 011912120031
Refered By : Self Sample Collection On : 12/Dec/2019 06:55AM
Collected By :SHUBHAM RAJPUT Sample Lab Rec.On :12/Dec/2019 12:35 PM
Collection Mode :HOME COLLECTION Reporting On :12/Dec/2019 02:17 PM
BarCode :10131251

AAROGYA EXECUTIVE PACKAGE 109 TEST

CASTS Negative Negative
CRYSTALS Negative Negative
EPITHELIAL CELLS 1-2 0-5 /HPF
BACTERIA Absent Absent

*** End Of Report ***

The parameter marked with * is not accredited by NABL

Page 16 of 16